KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Gross Margin (2016 - 2025)

Historic Gross Margin for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to 41.36%.

  • Pacific Biosciences Of California's Gross Margin rose 163300.0% to 41.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.4%, marking a year-over-year increase of 41500.0%. This contributed to the annual value of 24.21% for FY2024, which is 21100.0% down from last year.
  • According to the latest figures from Q3 2025, Pacific Biosciences Of California's Gross Margin is 41.36%, which was up 163300.0% from 36.93% recorded in Q2 2025.
  • In the past 5 years, Pacific Biosciences Of California's Gross Margin ranged from a high of 46.55% in Q4 2021 and a low of 3.69% during Q1 2025
  • For the 5-year period, Pacific Biosciences Of California's Gross Margin averaged around 31.92%, with its median value being 32.68% (2023).
  • Within the past 5 years, the most significant YoY rise in Pacific Biosciences Of California's Gross Margin was 204400bps (2025), while the steepest drop was -327600bps (2025).
  • Over the past 5 years, Pacific Biosciences Of California's Gross Margin (Quarter) stood at 46.55% in 2021, then tumbled by -60bps to 18.79% in 2022, then decreased by -13bps to 16.4% in 2023, then surged by 56bps to 25.64% in 2024, then skyrocketed by 61bps to 41.36% in 2025.
  • Its Gross Margin was 41.36% in Q3 2025, compared to 36.93% in Q2 2025 and 3.69% in Q1 2025.